



CSL Research Acceleration Initiative

Seeking Expressions of Interest from Research Organisations

WHY COLLABORATE WITH CSL?



Global capabilities on your doorstep



Work with one of the world's leading biotech companies



Funding for successful proposals



Access to commercial R&D, clinical, intellectual property, marketing and manufacturing expertise



Accelerate translation of your research to deliver new **therapies** to patients

CSL is a leading global biotech company that develops and delivers innovative biotherapies to help people living with life-threatening medical conditions live full lives. CSL's Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and Australasian research organisations. These partnerships provide funding and access to industry resources for scientists working on novel biotherapeutic strategies in CSL's therapeutic areas. Expressions of interest are sought from Business Development / Commercialisation representatives within Australasian research organisations that wish to participate in the 2020 CSL Research Acceleration Initiative.

The 2020 Research Acceleration Initiative will focus on research projects that span a **CSL Therapeutic Area** and a **Focus Area**, and that are amenable to or include a **Modality** listed below:

THERAPEUTIC AREAS

(emphasis on rare disease)

- Immunology
- Neurology
- Haematology
- Thrombosis
- Transplant
- Respiratory
- Cardiovascular / Metabolic

FOCUS AREAS

- Novel drug targets
- Novel therapeutic candidates
- Novel strategies for treating disease

MODALITIES

- Antibodies
- Protein therapeutics
- Gene therapies
- Cell therapies
- Small molecules **not** of interest

CSL Research Acceleration Initiative



Additional Information

Register your research organisation

BD / Commercialisation representatives from Australasian research organisations (universities, medical research institutes, hospitals) are invited to register their organisation's interest to participate in the 2020 Research Acceleration Initiative by **emailing RAI@csl.com.au by 1st December 2019.**

Assign your primary contact

CSL requests that each research organisation nominate one BD / Commercialisation representative to be assigned as the primary contact for CSL.

Calls for scientific proposals

CSL will work with nominated BD / Commercialisation representatives from participating research organisations to seek scientific proposals that span a CSL Therapeutic Area and a CSL Focus Area, and that are amenable to or include a CSL Modality listed over the page. Scientists from Australasian research organisations interested in applying for funding should coordinate submissions with their BD / Commercialisation representatives directly. It is anticipated that calls for research proposals will open in March 2020.

Limitations on submissions

Each participating research organisation will be invited to submit up to three research proposals.

Funding

CSL will fund up to three proposals across the 2020 Research Acceleration Initiative. Successful applicants will receive up to \$250,000 per year for up to two years (maximum \$500,000 funding) to accelerate translation of their research.

